Antiproliferative and MDR reversal property
Acknowledgments
and related compounds. Eur J Med Chem;35:967–
9
77.
We are acknowledged with gratitude for financial support
from National Natural Science Foundation of China (No.
9. Silverman R.B. (1992) The Organic Chemistry of Drug
Design and Drug Action. San Diego: Academic Press
Inc.; p. 220–222.
21402010), the Natural Science Foundation of Shandong
Province (Nos. ZR2014BL008, ZR2013BM022), the
Youth Science Foundation of Shandong Province
10. Chien C.I., Kirollos K.S., Linderman R.J., Dauterman
W.C. (1994) Alpha, beta -unsaturated carbonyl com-
pounds: inhibition of rat liver glutathione S-transferase
isozymes and chemical reaction with reduced glu-
tathione. Biochim Biophys Acta;1204:175–180.
(2015GGX102013), the Foundation of higher institution of
Shandong Province (J11LF27), and the Foundation of
Yantai (Nos. 2013ZH095, 2011076, 2015WS010).
1
1. Dimmock J.R., Elias D.W., Beazely M.A., Kandepu
N.M. (1999) Bioactivities of chalcones. Curr Med
Chem;6:1125–1149.
Conflict of Interest
1
2. Das U., Gul H.I., Alcorn J., Shrivastav A., George T.,
Sharma R.K., Nienaber K.H. et al. (2006) Cytotoxic 5-
aryl-1-(4-nitrophenyl)-3-oxo-1,4-pentadienes mounted
on alicyclic scaffolds. Eur J Med Chem;41:577–585.
All authors declare no conflict of interest.
References
13. Das S., Das U., Sakagami H., Umemura N., Iwamoto
S., Matsuta T., Kawase M., Moln aꢀ r J., Serly J., Gorecki
1
2
3
4
5
. Amslinger S. (2010) The tunable functionality of a, b-
unsaturated carbonyl compounds enables their differ-
D.K.J., Dimmock J.R. (2012) Dimeric 3,5-bis(benzyli-
dene)-4- piperidones: a novel cluster of tumour-
selective cytotoxins possessing multidrug-resistant
properties. Eur J Med Chem;51:1193–1199.
ential
application
in
biological
systems.
ChemMedChem;5:351–356.
14. Das U., Moln
aꢀ r J., Bar aꢀ th Z., Bata Z., Dimmock J.R.
. Issaenko O.A., Amerik A.Y. (2012) Chalcone-based
small-molecule inhibitors attenuate malignant pheno-
type via targeting deubiquitinating enzymes. Cell
Cycle;11:1804–1817.
. Liu Y.-C., Hsieh C.-W., Wu C.-C., Wung B.-S. (2007)
Chalcone inhibits the activation of NF-jB and STAT3 in
endothelial cells via endogenous electrophile. Life
Sci;80:1420–1430.
. Kadoma Y., Fujisawa S. (2007) Comparative radical-
scavenging activity of curcumin and tetrahydrocurcumin
with thiols as measured by the induction period method.
In Vivo;21:979–982.
. Tawari N.R., Bairwa R., Ray M.K., Rajan M.G.R.,
Degani M.S. (2010) Design, synthesis, and biological
(2008) 1-[4-(2-Aminoethoxy) phenylcarbonyl]-3,5-bis-
(benzylidene)-4-oxopiperidines: a novel series of highly
potent revertants of P-glycoprotein associated multidrug
resistance. Bioorg Med Chem Lett;18:3484–3487.
15. Dei S., Coronnello M., Floriddia E., Bartolucci G., Bel-
lucci C., Guandalini L., Manetti D., Romanelli M.N.,
Salerno M., Bello I., Mini E., Teodori E. (2014) Mul-
tidrug resistance (MDR) reversers: high activity and effi-
cacy in a series of asymmetrical N,N-bis(alkanol)amine
aryl esters. Eur J Med Chem;87:398–412.
16. Leonard G.D., Polgar O., Bates S.E. (2002) ABC trans-
porters and inhibitors: new targets, new agents. Curr
Opin Investig Drugs;3:1652–1659.
evaluation
of
4-(5-nitrofuran-2-yl)prop-2-en-1-one
17. Krishna R., Mayer L.D. (2000) Multidrug resistance
(MDR) in cancer. Mechanisms, reversal using modula-
tors of MDR and the role of MDR modulators in influ-
encing the pharmacokinetics of anticancer drugs. Eur
J Pharm Sci;11:265–283.
18. Walker J., Martin C., Callaghan R. (2004) Inhibition of
P-glycoprotein function by XR9576 in a solid tumour
model can restore anticancer drug efficacy. Eur J
Cancer;40:594–605.
19. Morschhauser F., Zinzani P.L., Burgess M., Sloots L.,
Bouafia F., Dumontet C. (2007) Phase I/II trial of a P-
glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochlo-
ride (LY335979), given orally in combination with the
CHOP regimen in patients with non-Hodgkin’s lym-
phoma. Leuk Lymphoma;48:708–715.
20. Wesolowska O., Paprocka M., Kozlak J., Motohashi N.,
Dus D., Michalak K. (2005) Human sarcoma cell lines
MES-SA and MES-SA/Dx5 as a model for multidrug
resistance modulators screening. Anticancer Res;25:
383–389.
derivatives as potent antitubercular agents. Bioorg Med
Chem Lett;20:6175–6178.
. Kawase M., Sakagami H., Motohashi N., Hauer H.,
Chatterjee S.S., Spengler G., Vigyikanne A.V., Moln aꢀ r
A., Moln aꢀ r J. (2005) Coumarin derivatives with tumor-
specific cytotoxicity and multidrug resistance reversal
activity. In Vivo;19:705–712.
. Bazzaro M., Anchoori R.K., Mudiam M.K.R., Issaenko
O., Kumar S., Karanam B., Lin Z.H., Vogel R.I., Gavioli
R., Destro F., Ferretti V., Roden R.B.S., Khan S.R.
6
7
(2011) α,b-Unsaturated carbonyl system of chalcone-
based derivatives is responsible for broad inhibition of
proteasomal activity and preferential killing of human
papilloma virus (HPV) positive cervical cancer cells. J
Med Chem;54:449–456.
. Dimmock J.R., Kumar P., Nazarali A.J., Motaganahalli
N.L., Kowalchuk T.P., Beazely M.A., Quail J.W., Oloo
E.O., Allen T.M., Szydlowski J., Clercq E.D., Balzarini
J. (2000) Cytotoxic 2,6-bis(arylidene) cyclohexanones
8
Chem Biol Drug Des 2016
7